Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment for peanut allergy

A technology for peanut allergy and peanut powder, applied in allergic diseases, antibody medical ingredients, medical preparations containing active ingredients, etc., can solve problems such as increased risk of unintentional ingestion

Inactive Publication Date: 2014-02-19
CAMBRIDGE ENTERPRISE LTD +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nearly a third of children with nut allergies are unaware that they are allergic to the nut - a lack of awareness that puts them at increased risk of inadvertent ingestion [9]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment for peanut allergy
  • Treatment for peanut allergy
  • Treatment for peanut allergy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0104] experiment

[0105] method 1

[0106] The study was approved by the Local Ethics and Research and Development Committees and written informed consent was given to each family. Inclusion criteria were positive peanut oral (immunization) challenge and presence of peanut-specific IgE in children 4-18 years of age. Severe immunodeficiency and inability to comply with the study protocol were exclusion criteria. 22 children were selected. Children with a history of anaphylaxis following peanut ingestion were included.

[0107] Skin prick test (SPT) (peanut extract, saline negative control and histamine 10mg / mL positive control; single point lancet; ALK-Abello, Denmark ), peanut SPT was interpreted as positive when the wheal diameter was at least 3 mm larger than the negative control. Serum analysis was performed for whole peanut and Ara h2-specific IgE (CAP-Systems FEIA; Phadia, Uppsala, Sweden).

[0108] Double-blind placebo-controlled food challenge (DBPCFC)

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2mg, 5mg, 12.5mg, 25mg, 50mg, 0mg, 200mg, 400mg and 800mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years.

Description

technical field [0001] The present invention relates to the treatment of peanut allergy by oral immunotherapy (OIT). Background technique [0002] Peanut allergy is common, affecting 1 to 2 percent of young children in Europe and the United States [1-3], unlike other common childhood food allergies (eg, egg allergy), resolution of which is less common[ 4]. The quality of life of affected families is reduced by the constant fear of food choices and the possibility of allergic reactions [5, 6]. Families of children with peanut allergy are poorly informed about how to avoid and treat food allergy emergency visits despite the best available treatments [7]. Unintended reactions are common (annual incidences of 3%, 14%, and 50% have been reported in numerous studies [8]). Nearly one-third of children with nut allergies are unaware that they are allergic to the nut—a lack of awareness that puts them at increased risk of inadvertent ingestion [9]. Therefore, it is necessary to d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/35
CPCA61K2039/545A61K39/35A61K2039/542A61P37/08C07K14/415
Inventor 安德鲁·克拉克帕米拉·尤安
Owner CAMBRIDGE ENTERPRISE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products